

## lanthanum carbonate (FOSRENOL)

### Diagnoses Considered for Coverage:

- Reduce serum phosphate in patients with end stage renal disease who have hyperphosphatemia

### Coverage Criteria:

#### For diagnosis listed above:

- Patient has chronic kidney disease that requires dialysis, **and**
- Inadequate response, intolerable side effect, or contraindication to BOTH calcium acetate (PhosLo) and sevelamer carbonate (Renvela, Renagel), **and**
- Dose does not exceed FDA maximum.

### Coverage Duration: one year

#### References:

1. Fosrenol. Prescribing Information. Takeda Pharmaceuticals America, Inc. Lexington, MA. 5.2023
2. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements (2017) 7, 1-59.

Effective Date: 09/27/2023